Clinical trial · Observational
Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Through this study, the investigators seek to identify the benefits (improved survival) and harms (more procedures, more treatment, side effects, and quality-of-life impact) from different surveillance frequencies-every three vs. six vs. 12 months. Using the National Cancer Database and quality-of-life data from a large group of prostate cancer survivors, the investigators aim to compare survival, procedures/tests, treatments, and side effects in prostate cancer survivors who are followed with alternative surveillance frequencies and compare quality-of-life outcomes. The overall goal of the study is to provide high-quality data that will allow development of a personalized, risk-based tailored approach to post-treatment surveillance for prostate cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Prostate | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Cancer of the Prostate | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
| Prostatic Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- National Cancer Data Base
- description
- Patients within the National Cancer Database with newly diagnosed prostate cancer between 2004 and 2010. Participating institutions each provided a random of sample of 10 patients to be included in the final cohort.
- label
- NC ProCESS
- description
- The North Carolina Prostate cancer Comparative Effectiveness \& Survivorship Study (NC ProCESS) is a prospective population-based cohort of \>1,000 patients with newly diagnosed prostate cancer, enrolled from January 2011 through June 2013.
Primary outcomes (2)
- measure
- Overall Survival
- timeFrame
- From completion of primary treatment with surgery or radiation to the earliest occurrence of death, loss to follow-up, or the end of the study period.
- description
- Time to death or date of last follow-up after primary treatment with surgery or radiation.
- measure
- Prostate Cancer Anxiety
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria for the National Cancer Data Base cohort: * Patient data part of the NCDB * Diagnosed with prostate cancer in 2004-2005. * Treated for prostate cancer with surgery (prostatectomy) or radiation therapy Inclusion/Exclusion Criteria for the NC ProCESS cohort: Inclusion Criteria: * Newly-diagnosed, histologically-proven, localized prostate adenocarcinoma. * Completion of baseline interview prior to initiating therapy. * Patient ability to complete study interview: no cognitive impairment, language or hearing problems. * Not diagnosed with prostate cancer through transurethral resection of the prostate (TURP). * Age 35-80. * English speaking. * Has telephone. Exclusion Criteria: * Initiation of treatment for prostate cancer prior to completion of baseline interview. * Cognitive impairment. * Hearing problems. * Inability to speak or understand English.
References
Publications (0)
Data not yet available